9 November 2016 – WTO TRIPS Council – UNCTAD’s statement on the Report of the UN High-Level Panel on Access to Medicines
On Wednesday, 9 November 2016, the United Nations Conference on Trade and Development (UNCTAD) delivered the following statement at the World Trade Organization’s (WTO) TRIPS Council’s discussions of the United Nations Secretary-General’s High Level Panel Report on Access to Medicines. UNCTAD informed WTO members that the agency had recently recommended to Secretary-General Ban Ki-moon to consider endorsement of the Report of the High Level Panel.
The Report of the United Nations High Level Panel on Access to Medicine
Continue ReadingSCCR 33: Argentina, Colombia and Mexico – Note on the Draft Treaty to Protect Broadcasting Organizations
On 8 November 2016, the World Intellectual Property Organization (WIPO) published a submission by Argentina, Colombia and Mexico entitled, “Note on the Draft Treaty to Protect Broadcasting Organizations” (SCCR/33/5). In their proposal, the proponents (Argentina, Colombia and Mexico) note that negotiations on a WIPO broadcast treaty have gone on for 18 years and 33 sessions of the Standing Committee on Copyright and Related Rights (SCCR). Continue Reading
India Patent Office denies patent for prostate cancer drug sold under brand name Xtandi, generic name enzalutamide
Updated
According to this story, the India Patent Office has denied a patent for the prostate cancer drug sold under the brand name Xtandi (generic name Enzalutamide). Opponents of the patent claimed it was a new form of a known substance, and not eligible in India under Section 3(d) of its patent act.9 November 2016 – WTO TRIPS Council – India’s intervention on the Report of the UN High-Level Panel on Access to Medicines
On Wednesday, 9 November 2016, India delivered the following statement at the World Trade Organization’s (WTO) TRIPS Council’s discussions of the United Nations Secretary-General’s High Level Panel Report on Access to Medicines.
Agenda item 13: the United Nations Secretary-General’s High Level Panel Report on Access to Medicines
Statement by India.
Thank you Chairman.
At the outset, I would like to thank delegations of Brazil, China and South Africa who are also co-sponsors of this agenda item.
9 November 2016 – WTO TRIPS Council – WHO’s intervention on the Report of the UN High-Level Panel on Access to Medicines
On Wednesday, 9 November 2016, the World Health Organization (WHO) delivered the following statement at the World Trade Organization’s (WTO) TRIPS Council’s discussions of the United Nations Secretary-General’s High Level Panel Report on Access to Medicines.
COUNCIL FOR TRIPS
8-9 NOVEMBER 2016
WHO STATEMENT
13. THE UNITED NATIONS SECRETARY-GENERAL’S HIGH LEVEL PANEL REPORT ON ACCESS TO MEDICINES
Thank you very much for giving WHO the opportunity to share our feedback on the Report of the High-Level Panel on Access to Medicines.
9 November 2016 – WTO TRIPS Council – Brazil’s intervention on the Report of the UN High-Level Panel on Access to Medicines
On 9 November 2016, the World Trade Organization’s (WTO) TRIPS Council held discussions on the United Nations Secretary-General’s High-Level Panel Report on Access to Medicines (UN HLP). These timely WTO discussions on the UN HLP germinated from a 27 October 2016 request by Brazil, China, India and South Africa requesting the WTO Secretariat to place a dedicated agenda item for consideration at the 8-9 November 2016 session of the TRIPS Council entitled “the United Nations Secretary-General’s High-Level Panel Report on Access to Medicines.”
Lancet Commission on Essential Medicines Policies publishes 74 page report, endorses delinkage of R&D costs from drug prices
Today The Lancet Commission on Essential Medicines Policies published the 74 page report on “Essential Medicines for Universal Health Coverage.” A copy is available here.
The report is rich in data, analysis and recommendations. The report endorses the delinking of R&D costs from drug prices:
Delinking R&D costs from the price of medicines
Some measures that a new President and/or Congress can take to lower drug prices in the near term
KEI and others working in the drug pricing space are frequently asked about measures that a new President or Congress can take to lower drug prices, in the relatively near term. The following is a list of such actions, including some that would require legislation and some that would not.
A comprehensive list of possible actions would be much longer, and this is not such a list. Our list does not include suggestions from several other groups working on drug pricing that deserve consideration, and there is nothing at this point on price spikes.
WTO TRIPS Council – Brazil, China, India and South Africa request discussion of the UN High-Level Panel on Access to Medicines
On Thursday, 27 October 2016, Brazil, China, India and South Africa submitted a communication (IP/C/W/619) to the World Trade Organization (WTO) requesting the WTO Secretariat to “place a dedicated agenda item for consideration at the 8-9 November 2016 session of the TRIPS Council entitled “the United Nations Secretary-General’s High-Level Panel Report on Access to Medicines.” In the WTO submission, Brazil, China, India and South Africa enclosed the entire Final Report of the UN Secretary-General’s High-Level Panel on Access to Continue Reading
HIV revenues and industry investments in clinical trials for HIV
According to IMS, the global market for HIV antiviral drugs was $24.4 billion in 2015. Over the past three decades, drug companies have registered an average of one new molecular entity HIV ARV per year. This is a lot of money to spend on HIV drugs to induce just one new drug per year.
Today I took a look at data from the NIH clinicaltrials.gov database, to see what the industry was reporting in terms of trials.